ZA200303798B - Methods for modulating bladder function. - Google Patents
Methods for modulating bladder function. Download PDFInfo
- Publication number
- ZA200303798B ZA200303798B ZA200303798A ZA200303798A ZA200303798B ZA 200303798 B ZA200303798 B ZA 200303798B ZA 200303798 A ZA200303798 A ZA 200303798A ZA 200303798 A ZA200303798 A ZA 200303798A ZA 200303798 B ZA200303798 B ZA 200303798B
- Authority
- ZA
- South Africa
- Prior art keywords
- dihydro
- chloro
- indol
- alkyl
- hydroxy
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 26
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 claims description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 239000001257 hydrogen Substances 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 16
- 206010046543 Urinary incontinence Diseases 0.000 claims description 15
- 230000002265 prevention Effects 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 11
- 108010022282 KCNQ Potassium Channels Proteins 0.000 claims description 10
- 102000012359 KCNQ Potassium Channels Human genes 0.000 claims description 10
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims description 10
- 239000000460 chlorine Substances 0.000 claims description 10
- 150000002431 hydrogen Chemical group 0.000 claims description 10
- 102000004257 Potassium Channel Human genes 0.000 claims description 9
- 108020001213 potassium channel Proteins 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- QNLOWBMKUIXCOW-UHFFFAOYSA-N indol-2-one Chemical compound C1=CC=CC2=NC(=O)C=C21 QNLOWBMKUIXCOW-UHFFFAOYSA-N 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 206010046494 urge incontinence Diseases 0.000 claims description 6
- 101000994648 Homo sapiens Potassium voltage-gated channel subfamily KQT member 4 Proteins 0.000 claims description 5
- 206010020880 Hypertrophy Diseases 0.000 claims description 5
- 108010006746 KCNQ2 Potassium Channel Proteins 0.000 claims description 5
- 102100034354 Potassium voltage-gated channel subfamily KQT member 2 Human genes 0.000 claims description 5
- 210000002307 prostate Anatomy 0.000 claims description 5
- 108010038888 KCNQ3 Potassium Channel Proteins 0.000 claims description 4
- 102100034360 Potassium voltage-gated channel subfamily KQT member 3 Human genes 0.000 claims description 4
- 125000005605 benzo group Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000004494 ethyl ester group Chemical group 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 208000022170 stress incontinence Diseases 0.000 claims description 4
- 241000282414 Homo sapiens Species 0.000 claims description 3
- 102100034363 Potassium voltage-gated channel subfamily KQT member 4 Human genes 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- MUODZNLVEGXDBR-UHFFFAOYSA-N 3-(5-chloro-2-hydroxyphenyl)-1,3-dihydroindol-2-one Chemical compound OC1=CC=C(Cl)C=C1C1C2=CC=CC=C2NC1=O MUODZNLVEGXDBR-UHFFFAOYSA-N 0.000 claims description 2
- LMNFTYDGFXTVRA-UHFFFAOYSA-N 3-(5-chloro-2-methoxyphenyl)-3-hydroxy-6-(trifluoromethyl)-1h-indol-2-one Chemical compound COC1=CC=C(Cl)C=C1C1(O)C2=CC=C(C(F)(F)F)C=C2NC1=O LMNFTYDGFXTVRA-UHFFFAOYSA-N 0.000 claims description 2
- PWVWEVKKXHXJDJ-UHFFFAOYSA-N 3-[2-amino-3-[(2-chlorophenyl)methylamino]phenyl]-1,1-diethylurea Chemical compound CCN(CC)C(=O)NC1=CC=CC(NCC=2C(=CC=CC=2)Cl)=C1N PWVWEVKKXHXJDJ-UHFFFAOYSA-N 0.000 claims description 2
- HFYPMLZEHRHOQT-UHFFFAOYSA-N 3-[2-amino-4-[(2,4-dichlorophenyl)methylamino]phenyl]-1,1-dimethylurea Chemical compound C1=C(N)C(NC(=O)N(C)C)=CC=C1NCC1=CC=C(Cl)C=C1Cl HFYPMLZEHRHOQT-UHFFFAOYSA-N 0.000 claims description 2
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 2
- 241000282465 Canis Species 0.000 claims description 2
- 241000282324 Felis Species 0.000 claims description 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- KIKPFVWLJOWVQQ-UHFFFAOYSA-N ethyl n-[2-amino-4-(benzylamino)phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=CC=C1 KIKPFVWLJOWVQQ-UHFFFAOYSA-N 0.000 claims description 2
- MTOVOPJBHBJLOT-UHFFFAOYSA-N ethyl n-[2-amino-4-[(3,5-dichlorophenyl)methylamino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC(Cl)=CC(Cl)=C1 MTOVOPJBHBJLOT-UHFFFAOYSA-N 0.000 claims description 2
- DXXOREOJVZZYGH-UHFFFAOYSA-N ethyl n-[2-amino-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(C(F)(F)F)C=C1 DXXOREOJVZZYGH-UHFFFAOYSA-N 0.000 claims description 2
- MLASFMFVHONABG-UHFFFAOYSA-N n-[2-acetamido-4-[(4-fluorophenyl)methylamino]phenyl]acetamide Chemical compound C1=C(NC(C)=O)C(NC(=O)C)=CC=C1NCC1=CC=C(F)C=C1 MLASFMFVHONABG-UHFFFAOYSA-N 0.000 claims description 2
- UKWZNOAQKDPXSA-UHFFFAOYSA-N propyl n-[2-amino-4-[(3,5-dichlorophenyl)methylamino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCCC)=CC=C1NCC1=CC(Cl)=CC(Cl)=C1 UKWZNOAQKDPXSA-UHFFFAOYSA-N 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 11
- 229940122117 Potassium channel agonist Drugs 0.000 claims 6
- 125000004185 ester group Chemical group 0.000 claims 6
- LVGWICVJRKZXKB-UHFFFAOYSA-N 3-(5-chloro-2-methoxyphenyl)-3-fluoro-7-(trifluoromethyl)-1h-indol-2-one Chemical compound COC1=CC=C(Cl)C=C1C1(F)C(C=CC=C2C(F)(F)F)=C2NC1=O LVGWICVJRKZXKB-UHFFFAOYSA-N 0.000 claims 1
- CXDFALXRSFUORC-UHFFFAOYSA-N 5-bromo-3-(5-chloro-2-methoxyphenyl)-3-fluoro-1h-indol-2-one Chemical compound COC1=CC=C(Cl)C=C1C1(F)C2=CC(Br)=CC=C2NC1=O CXDFALXRSFUORC-UHFFFAOYSA-N 0.000 claims 1
- 229960003312 retigabine Drugs 0.000 description 22
- 210000003932 urinary bladder Anatomy 0.000 description 18
- 239000002775 capsule Substances 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 206010020853 Hypertonic bladder Diseases 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 5
- -1 Cs-Crcycloalkyl Chemical group 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 229940069328 povidone Drugs 0.000 description 5
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 4
- 101000994656 Homo sapiens Potassium voltage-gated channel subfamily KQT member 5 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102100034365 Potassium voltage-gated channel subfamily KQT member 5 Human genes 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- PAMMIXSSIGTOAK-UHFFFAOYSA-N 3-phenyl-1,3-dihydroindol-2-one Chemical class O=C1NC2=CC=CC=C2C1C1=CC=CC=C1 PAMMIXSSIGTOAK-UHFFFAOYSA-N 0.000 description 3
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 3
- 206010029279 Neurogenic bladder Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- ULYONBAOIMCNEH-HNNXBMFYSA-N (3s)-3-(5-chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)-1h-indol-2-one Chemical compound COC1=CC=C(Cl)C=C1[C@@]1(F)C2=CC=C(C(F)(F)F)C=C2NC1=O ULYONBAOIMCNEH-HNNXBMFYSA-N 0.000 description 2
- FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 description 2
- GMUVMLWENGMHNR-UHFFFAOYSA-N 3-(5-chloro-2-hydroxyphenyl)-3-hydroxy-6-(trifluoromethyl)-1h-indol-2-one Chemical compound OC1=CC=C(Cl)C=C1C1(O)C2=CC=C(C(F)(F)F)C=C2NC1=O GMUVMLWENGMHNR-UHFFFAOYSA-N 0.000 description 2
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- YEJCDKJIEMIWRQ-UHFFFAOYSA-N Linopirdine Chemical compound O=C1N(C=2C=CC=CC=2)C2=CC=CC=C2C1(CC=1C=CN=CC=1)CC1=CC=NC=C1 YEJCDKJIEMIWRQ-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010027566 Micturition urgency Diseases 0.000 description 2
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000005236 alkanoylamino group Chemical group 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960004281 desmopressin Drugs 0.000 description 2
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 2
- 229960002845 desmopressin acetate Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- SPIUTQOUKAMGCX-UHFFFAOYSA-N flavoxate Chemical compound C1=CC=C2C(=O)C(C)=C(C=3C=CC=CC=3)OC2=C1C(=O)OCCN1CCCCC1 SPIUTQOUKAMGCX-UHFFFAOYSA-N 0.000 description 2
- 229960000855 flavoxate Drugs 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 229960004248 linopirdine Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- YGNSHYRMOVKKSL-UHFFFAOYSA-N n-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]acetamide Chemical compound C1=C(N)C(NC(=O)C)=CC=C1NCC1=CC=C(F)C=C1 YGNSHYRMOVKKSL-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- WFXFYZULCQKPIP-UHFFFAOYSA-N prazosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 WFXFYZULCQKPIP-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- OTHYPAMNTUGKDK-UHFFFAOYSA-N (3-acetylphenyl) acetate Chemical compound CC(=O)OC1=CC=CC(C(C)=O)=C1 OTHYPAMNTUGKDK-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 1
- PTKSEFOSCHHMPD-SNVBAGLBSA-N 2-amino-n-[(2s)-2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide Chemical compound COC1=CC=C(OC)C([C@H](O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-SNVBAGLBSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- NTRUEJHCDYYQPV-UHFFFAOYSA-N 3-(5-chloro-2-hydroxyphenyl)-1,3-dihydrobenzo[g]indol-2-one Chemical compound OC1=CC=C(Cl)C=C1C1C(C=CC=2C3=CC=CC=2)=C3NC1=O NTRUEJHCDYYQPV-UHFFFAOYSA-N 0.000 description 1
- GEYOEKOXFSCBMN-UHFFFAOYSA-N 3-(5-chloro-2-hydroxyphenyl)-6-(trifluoromethyl)-1,3-dihydroindol-2-one Chemical compound OC1=CC=C(Cl)C=C1C1C2=CC=C(C(F)(F)F)C=C2NC1=O GEYOEKOXFSCBMN-UHFFFAOYSA-N 0.000 description 1
- YWASCLWHVWAJSD-UHFFFAOYSA-N 3-(5-chloro-2-methoxyphenyl)-3-fluoro-6-phenyl-1h-indol-2-one Chemical compound COC1=CC=C(Cl)C=C1C1(F)C2=CC=C(C=3C=CC=CC=3)C=C2NC1=O YWASCLWHVWAJSD-UHFFFAOYSA-N 0.000 description 1
- YYSCJLLOWOUSHH-UHFFFAOYSA-N 4,4'-disulfanyldibutanoic acid Chemical compound OC(=O)CCCSSCCCC(O)=O YYSCJLLOWOUSHH-UHFFFAOYSA-N 0.000 description 1
- MZOUVOQNHXITAB-UHFFFAOYSA-N 4-chlorobuta-1,3-diyn-1-ol Chemical compound OC#CC#CCl MZOUVOQNHXITAB-UHFFFAOYSA-N 0.000 description 1
- CERBOJDBMLXUJL-UHFFFAOYSA-N 6-[2-acetamido-5-[(4-fluorophenyl)methylamino]anilino]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound C1=C(NC2C(C(O)C(O)C(O2)C(O)=O)O)C(NC(=O)C)=CC=C1NCC1=CC=C(F)C=C1 CERBOJDBMLXUJL-UHFFFAOYSA-N 0.000 description 1
- BMSUQJOIKORXDG-UHFFFAOYSA-N 6-[4-acetamido-3-amino-n-[(4-fluorophenyl)methyl]anilino]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound C1=C(N)C(NC(=O)C)=CC=C1N(C1C(C(O)C(O)C(O1)C(O)=O)O)CC1=CC=C(F)C=C1 BMSUQJOIKORXDG-UHFFFAOYSA-N 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 108010011185 KCNQ1 Potassium Channel Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229940127343 Potassium Channel Agonists Drugs 0.000 description 1
- 229940127315 Potassium Channel Openers Drugs 0.000 description 1
- 102100037444 Potassium voltage-gated channel subfamily KQT member 1 Human genes 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 229940083335 Vasopressin agonist Drugs 0.000 description 1
- 229940116211 Vasopressin antagonist Drugs 0.000 description 1
- YVYBOBCEEPIDJV-UHFFFAOYSA-N [2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamic acid Chemical compound C1=C(NC(O)=O)C(N)=CC(NCC=2C=CC(F)=CC=2)=C1 YVYBOBCEEPIDJV-UHFFFAOYSA-N 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- JSYBAZQQYCNZJE-UHFFFAOYSA-N benzene-1,2,4-triamine Chemical class NC1=CC=C(N)C(N)=C1 JSYBAZQQYCNZJE-UHFFFAOYSA-N 0.000 description 1
- 210000005068 bladder tissue Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 229940087490 dibenzyline Drugs 0.000 description 1
- 229940099170 ditropan Drugs 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229960003210 hyoscyamine Drugs 0.000 description 1
- 229930005342 hyoscyamine Natural products 0.000 description 1
- 229960004173 hyoscyamine hydrobromide Drugs 0.000 description 1
- 229960001550 hyoscyamine sulfate Drugs 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- VDNVVLOBNHIMQA-UHFFFAOYSA-N iberiotoxin Chemical compound C1SSCC(C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(O)=O)NC(=O)C(CCCNC(N)=N)NC(=O)C1NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CCCNC(N)=N)NC(=O)C(CC(O)=O)NC(=O)C(C(C)C)NC(=O)CNC(=O)C(CC=1C=CC=CC=1)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CCCCN)NC1=O)CSSCC1NC(=O)C(C(C)C)NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(NC(=O)C(CCC(O)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)NC1=O)CSSCC1NC(=O)C(CC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(O)=O)NC(=O)C(C(C)O)NC(=O)C(NC(=O)C1NC(=O)CC1)CC1=CC=CC=C1 VDNVVLOBNHIMQA-UHFFFAOYSA-N 0.000 description 1
- 108010068927 iberiotoxin Proteins 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000012241 membrane hyperpolarization Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960001094 midodrine Drugs 0.000 description 1
- MGCQZNBCJBRZDT-UHFFFAOYSA-N midodrine hydrochloride Chemical compound [H+].[Cl-].COC1=CC=C(OC)C(C(O)CNC(=O)CN)=C1 MGCQZNBCJBRZDT-UHFFFAOYSA-N 0.000 description 1
- 229940064639 minipress Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 208000005346 nocturnal enuresis Diseases 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 150000005623 oxindoles Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000012402 patch clamp technique Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229960003418 phenoxybenzamine Drugs 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940117312 proamatine Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000004240 prostatic hypertrophy Diseases 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003553 tolterodine tartrate Drugs 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003038 vasopressin antagonist Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Description
METHODS FOR MODULATING BLADDER FUNCTION
. This invention relates to novel methods for modulating bladder tissues utilizing compounds which modulate the KCNQ family of potassium channels, particularly v 5 compounds which open or agonize the channels. The methods of this invention include the treatment, prevention, inhibition and amelioration of urge urinary incontinence also known as bladder instability, neurogenic bladder, voiding dysfunction, hyperactive bladder or detrusor overactivity. The methods of this invention also include the prevention and treatment of mixed stress and urge urinary incontinence, including that associated with secondary conditions such as prostate hypertrophy.
U.S. Patent No. 5,384,330 (Dieter et al) (EP 0554543B) teaches pharmacologically active 1,2,4-triaminobenzene derivatives of the General Formula: fe
Ne
Ar~Alk-(COM_ II © r-Alk-
NRyR,
Rs (0) and their properties as anti-epileptic, muscle relaxing, fever-reducing and peripheral analgesic agents.
U.S. Patent No. 5,565,483 (Hewawasam et al.) (EP 0747354B) teaches compounds of the formulae:
Rr!
R2 y (Lo
R3
R* R 5 . OR ng (n wherein: R is hydrogen, hydroxy or fluoro; R', R?, R® and R* each are independently hydrogen, Ci.4 alkyl, halogen, trifluoromethyl, phenyl, p-methyliphenyl or p-trifluoromethyl- . phenyl; or R' and R?, R? and R® or R% and R* are joined together to form a benzo fused ring; R® is hydrogen or C.; alkyl; and R® is chlorine or trifluoromethyl; or a nontoxic ' 5 pharmaceutically acceptable salt, solvate or hydrate thereof, which are potassium channel openers useful for treating ischemia, convulsions and asthma.
The article Modulation of KCNQ2/3 Potassium Channels by the Novel
Anticonvulsant Retigabine, Main et al., Molecular Pharmacology, 58: pp. 253-262, 2000, describes the actions of retigabine (D23129; N-[2-amino-4-(4-fluorobenzylamino)- phenyljcarbamic acid ethy! ester) in modulating the KCNQ2/3 potassium channels in oocytes in a 3-fold manner, i.e. retigabine shifts the voltage dependence of channel activation to more hyperpolarized membrane potentials, increases the rate of channel activation and slows channel deactivation. The article “KCNQ4 Channel Inactivation by
BMS-204352 and Retigabine” R L Schroder et al Neuropharmacology 40, 888-898 (2000) describes the activation of KCNQ4 channels in a reversible and concentration- dependent manner using retigabine and BMS-204352; (3S)-(+)-(5-chloro-2-methoxy- phenyl)-1,3-dihydro-3-fiuoro-6-(trifluoro-methyl))-2H-indol-2-one.
U.S. Patent No. 5,849,789 and 5,852,053 (bath to Rostock et al.) teache the use of retigabine for the treatment of neurodegenerative disorders, including those associated with stroke.
U.S. Patent No. 5,914,425 (Meisel et al.) teaches novel crystalline forms of retigabine.
U.S. Patent No. 6,117,900 teaches the use of retigabine, also known as N-[2- amino-4-(4-fluorobenzylamino)-phenyljcarbamic acid ethyl ester, for the treatment of neuropathic pain. . 30 -D.
Description of the invention . This invention comprises methods for modulating urinary bladder tissues in a mammal, particularly including uses thereof for maintaining urinary bladder control, the ’ 5 methods comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound which acts as an agonist or opener of the KCNQ family of potassium channels, including the KCNQ2, KCNQ3, KCNQ4, and KCNQ5 potassium channels, alone or in combination. A particular embodiment of this invention includes use in the methods described herein of one or more agonists or openers of KCNQ2/3 potassium channels. Another series of methods of this invention comprises use of one or more agonists or openers of KCNQ3/5 potassium channels.
Among the compounds useful in the methods of this invention are those disclosed in U.S. Patent No. 5,384,330 (Dieter et al.) and EP 0554543B, the contents of which are incorporated herein by reference. The compounds include those of the formula:
Raq i
Ar-Alk-(CO x ©
NN NR4Rs b wherein:
R, is selected from hydrogen, C—Cs-alkyl, C;—Ce-alkanoy! or the radical Ar;
R. is selected from hydrogen or C—Cs-alkyl;
R, is selected from C;—Cg-alkoxy, NH, C1—Cg-alkylamino, C1—Cg-dialkylamino, amino substituted by the radical Ar, C;—Cg-alkyl, Co—Cg-alkenyl, Co—Ce- alkynyl, the radical Ar or the radical ArO-,
R, is selected from hydrogen, Ci—Cs-alky! or the radical Ar; . 25 Rs is selected from hydrogen or C;—Cs-alkyl or the radical Ar,
Alk indicates a straight or branched alkylene group with 1-9 carbon atoms, which , can also be substituted by the radical Ar,
Ar is a phenyl radical substituted by the radicals Rs, R; and/or Rg where these radicals Rg, BR, and Rg are the same or different and represent H, Ci-Cs- * alkyl, Cs-Crcycloalkyl, hydroxy, GC;-Ce-alkoxy, Cz-Ce-alkanoyloxy, halogen, hydroxy, C;-Cg-halogenoalky!, -CN, -NH, -NH—C;-Cg-alkyl, * 5 -N(C4-Ce-alkyl)z, -COzH, -CO—C;-Cg-alkyl, -CO—0O—C;-Ce-alkyl, -COAr, -CO—OAr, -CONH,, -CONH—C;-Cg-alkyl, -CON(C4-Cg-alkyl)z, -CONHAT, -NH-CO—C;-Cg-alkyl, -NHCO—Ar, -NHCO-C;-Ce-alkoxy, -N-H-CO-Ar, “NHCO—NH,, -NHCO—N(-C-Cg-alkyl)s, -NHCO-NHAr, -NH-SO,-C4-Ce- alkyl, -NH—SO,Ar, -NH—SO,-nitrophenyl, -SO,-OH, -S0,—C;-Ce-alkyl, -SO4-Ar, -S0,—C;-Cg-alkoxy, -SO-OAr, -SO,-NHz, -SO2-NH-C1-Ce-alkyl, -SO,—N(C;-Ce-alkyl)z, -SO,-NHAr, -SO,-C+-Ce-alkoxy; nisOori; or a pharmaceutically acceptable salt thereof.
The alkyl! groups, halogenaiky! groups, alkenyl groups, alkynyl groups, alkoxy groups, alkylamino groups, alkanoy! amino groups, alkanoyloxy groups and alkanoyl groups in general can be straight or branched. The same aiso applies to alkyl and alkyloxy groups (=alkoxy groups) if these are components of more complicated radicals for example in the form of a monoalkyl- or dialkylamino group, alkanoylamino group, carbalkoxy group, alkylcarbonyl group and analogous groups. The Cs—GCr-cycloalkyl group is preferably cyclopentyl or cyclohexyl. C,—Cg-alkenyl preferably represents allyl.
C.—Cgs-alkynyl preferably represents propargyl.
The halogen atoms are chlorine, bromine or fluorine, in particular chlorine of fluorine. The alkyl and alkoxy groups as such or as components of groups of more complicated radicals consist in particular of 1-4 carbon atoms, preferably 1 or 2 carbon atoms. Alkanoyl groups, such as alkanoylamino groups or alkanoyloxy groups consist in particular of 2-4, preferably 2-3 carbon atoms. Alk consists in particular of 1-3, preferably 1 or 2 carbon atoms.
R 30
Among the more preferred compounds of this group are: , 2-Amino-4-(4-fluorobenzylamino)-1-ethoxycarbonylaminobenzene; 2-Amino-4-(4-trifluoromethylbenzylamino)-1-ethoxycarbonylamino-benzene;
2-Amino-4-benzylamino-1-ethoxycarbonylamino-benzene; 2-Amino-4-(3,5-dichlorobenzylamino)-1-ethoxycarbonylamino benzene; ' 2-Amino-4-(3,5-dichlorobenzylamino)-1-propyloxycarbonylamino benzene; 2-Amino-(2-chlorobenzylamino)-1-(diethylcarbamoylamino) benzene; ’ 5 2-Amino-4-(2,4-dichlorobenzylamino)-1-(dimethylcarbamoylamino) benzene; and 1,2-Diacetylamino-4-(4-fluorobenzylamino) benzene.
Among the most preferred compounds for use in the methods of this invention are N-[2-amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid and its pharmaceutically acceptable salts and ester forms. Of particular preference is retigabine, also known as
N-[2-amino-4-(4-fluorobenzylamino)-phenyllcarbamic acid ethyl ester (CAS Registry No. 150812-12-7), having the formula:
HN NH Va
OI
NH,
Also useful in the methods of this invention are the metabolite forms of retigabine which may be isolated from blood, urine or feces of recipients of N-[2-amino-4-(4- fluorobenzylamino)-phenyljcarbamic acid ethyl ester. The metabolites include the glucoside of retigabine, [4-(4-Fluoro-benzylamino)-2-(3,4,5-trihydroxy-6-hydroxymethyl- tetrahydropyran-2-ylamino)-phenyl}-carbamic acid ethyl ester, as well as its two glucoronide analogs, 6-[2-Ethoxycarbonylamino-5-(4-fluoro-benzylamino)-phenylamino}- 3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid and 6-[(3-Amino-4-ethoxycarbonyl- amino-phenyl)-(4-fluoro-benzyl)-amino)-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid. Further metabolites include N-[2-Amino-4-(4-fluoro-benzylamino)-phenyl]- acetamide, its cyclized analog (4-Fluoro-benzyl)-2-methyl-1H-benzoimidazol-5-yl)amine and the glucoronide analogs of N-[2-Amino-4-(4-fluoro-benzylamino)-phenyl]acetamide, 6-[(4-Acetylamino-3-amino-phenyl)-(4-fluoro-benzyl)-amino]-3,4,5-trihydroxy-tetrahydro- pyran-2-carboxylic acid and 6-[2-Acetylamino-5-(4-fluoro-benzylamino)-phenylamino]- 3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid.
Also useful in the methods of this invention are the compounds disclosed in U.S.
Patent No. 5,565,483 (Hewawasam et al.), which issued on October 15, 1996, and EP . 0747354B, the contents of which are incorporated herein by reference. These compounds include the substituted 3-phenyl oxindole compounds having the formulae: v A! 0)
R3 R
R* 7) OR®
R® (an wherein:
R is hydrogen, hydroxy or fluoro;
R', R? R® and R* each are independently hydrogen, Ci. alkyl, halogen, trifluoromethyl, phenyl, p-methylphenyl or p-trifluoromethylphenyl; or R' and R? R? and
R®or R®and R* are joined together to form a benzo fused ring;
R®is hydrogen or Cy.4 alkyl; and
R® is chlorine or trifluoromethyl; or a nontoxic pharmaceutically acceptable salt, solvate or hydrate thereof, and optical forms thereof.
One group of the substituted 3-phenyl oxindole compounds useful with this invention include those described above wherein R is hydrogen. Another subgroup of these compounds include those in which R', R?, R® and R* are each independently selected from H, C4 to C4 alkyl, halogen or trifluoromethy!, and when R' and R* are H; R? or R® is phenyl, p-methoxypheny! or trifluormethylphenyl; or R' and R?, R? and R®, or R® and R* are joined together to form a benzo fused ring; R5 is H or C, to C, alkyl; and R® is chlorine or trifluoromethyl, or a pharmaceutically acceptable salt form thereof.
Non-limiting examples of these substituted 3-pheny! oxindole compounds are: . 25 (+)-3-(5-Chioro-2-methoxyphenyl)-1 ,3-dihydro-3-hydroxy-6-(triflucromethyl)-2H-indol-2- one; , ()-3-(5-Chloro-2-methoxyphenyl)-1 ,3-dihydro-6-(trifluoromethyl)-2H-indol-2-one;
(1)-3-(5-Chlora-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2- one;
) (1)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-6-(trifluoromethyl)-2H-indol-2-one; (1)-3-(5-Chloro-2-hydroxyphenyl)-4,6-dichloro-1,3-dihydro-3-hydroxy-2-H-indol-2-one;
’ 5 (4)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-7-(trifluoromethyl)-2H-indol-2- one; (2)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-4-trifluoromethyl)2H-indol-2-one; (3)-1,3-Dihydro-3-hydroxy-3-[2-hydroxy-5-(trifluoromethyl)phenyi]-6-(trifluoromethyl)-2H- indol-2-one;
(4)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-4,6-bis(trifluoromethyl)-2H-indol- 2-one; (-)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2- one; (+)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2-
one;
(-)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6- (trifluoromethyl)-2H-indol-2- one; ()-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one; (+)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-2H-benz[glindol-2one;
(%)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-6-phenyl-2H-indol-2-one; (+)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-2H-benz[g]indol-2-one; (+)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-phenyl-2H-indol-2-one; (1)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-iodo-2H-indol-2one; (1)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-6-(4-methylphenyl)-2H-indol-2-one;
()-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-7-(trifluoromethyl)-2H-indol-2-one; ()-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-2H-benz[e)indol-2-one; (£)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-5-methyl-2H-indol-2-one; (£)-3-(5-Chloro-2-methoxyphenyl)-1 ,3-dihydro-3-fluoro-4,6-bis(triflucromethyl)-2H-indol-
. 2-one;
(4)-5-Bromo-3-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-2H-indol-2one;
. (£)-3-(5-Chloro-2-hydroxyphenyl)-1 ,3-dihydro-6-[4-(trifluoromethyl)phenyl]-2H-indol-2- one;
(+)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-2H-indol-2-one; (£)-5-Bromo-3-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-2H-indol-2-one; ) (2)-3-(5-Chioro-2-hydroxyphenyl)-4,6-dichloro-1,3-dihydro-2H-indol-2-one; (£)-3-(5-Chlioro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-6-iodo-2H-indol-2-one;, (%)-3-(5-Chloro-hydroxyphenyl)-1,3-dihydro-6-iodo-2H-indol-2-one; (+)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-2H-benz[flindol-2one; (+)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-2H-benz[f}indol-2one; and (£)-83-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-2H-benz[flindol-2-one; and the pharmaceutically acceptable salt forms thereof.
Among the more preferred compounds of this group are:
Cl
F
SUQas
F
OH NH
0 (+)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-6-(trifluoromethyl)-2H-indol-2-one;
Ci
HO" ©
HO—C F
A i
N
© H (+)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2-one;
Cl ~ 0 F
F—C F . PR E 0 N
H v (2)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one;
HO
OH aS
N° "0 Cl (+)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-2H-benz[glindol-2-one;
Cl oo” H (+)-3-(5-Chloro-2-hydroxypheny!)-1,3-dihydro-6-phenyl-2H-indol-2-one; and (°
HO
O
Sas (+)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-2H-benz[flindol-2-one.
Pharmaceutically acceptable salt forms of these substituted 3-phenyl oxindole compounds include those formed as base addition, including those formed using suitable inorganic bases, such as alkali and alkaline earth metal bases, such as sodium, potassium, magnesium and calcium metallic cations. The compounds may be administered as described in U.S. Patent No. 5,565,483. A pharmaceutically effective amount in mammals, including man, may be from about 0.1 pg/kg to about 100 mg/kg of , body weight. Parenteral administration may be completed at an effective dose of from about 1 ng/kg to about 10 mg/kg of body weight. . 15
The methods of this invention are useful for inducing, assisting or maintaining desirable bladder control in a mammal experiencing or susceptible to bladder instability ’ or urinary incontinence. These methods include prevention, treatment or inhibition of bladder-related urinary conditions and bladder instability, including nocturnal enuresis, ) 5 nocturia, voiding dysfunction and urinary incontinence. Also treatable or preventable with the methods of this invention is bladder instability secondary to prostate hypertrophy. The compounds described herein are also useful in promoting the temporary delay of urination whenever desirable. The compounds of this invention may also be utilized to stabilize the bladder and treat or prevent incontinence which urge urinary incontinence, stress urinary incontinence or a combination of urge and stress incontinence in a mammal, which may also be referred to as mixed urge and stress incontinence. These methods include assistance in preventing or treating urinary incontinence associated with secondary conditions such as prostate hypertrophy.
These methods may be utilized to allow a recipient to control the urgency and frequency of urination. The methods of this invention include the treatment, prevention, inhibition and amelioration of urge urinary incontinence also known as bladder instability, neurogenic bladder, voiding dysfunction, hyperactive bladder, detrusor overactivity, detrusor hyper-refiexia or uninhibited bladder.
As described above, methods of this invention include treatments, prevention, inhibition or amelioration of hyperactive or unstable bladder, neurogenic bladder or hyperreflexic bladder. These uses include, but are not limited to, those for bladder activities and instabilities in which the urinary urgency is associated with prostatitis, prostatic hypertrophy, interstitial cystitis, urinary tract infections or vaginitis. The methods of this invention may also be used to assist in inhibition or correction of the conditions of Frequency-Urgency Syndrome, and lazy bladder, also known as infrequent voiding syndrome.
The methods of this invention may also be used to treat, prevent, inhibit, or limit . the urinary incontinence, urinary instability or urinary urgency associated with or resulting from administrations of other medications, including diuretics, vasopressin antagonists, . anticholinergic agents, sedatives or hypnotic agents, narcotics, alpha-adrenergic agonists, alpha-adrenergic antagonists, or calcium channel blockers.
The methods of this invention are useful for inducing or assisting in urinary : bladder control or preventing or treating the maladies described herein in humans in need of such relief, including adult and pediatric uses. However, they may aiso be ' 5 utilized for veterinary applications, particularly including canine and feline bladder control methods. If desired, the methods herein may also be used with farm animals, such as ovine, bovine, porcine and equine breeds.
The applications may utilize conventional oral, rectal, parenteral or intravenous delivery methods as conventionally utilized in veterinary practice. Most preferable in most instance for home use with companion animals are oral tablets or capsules or neat compound or powdered or granular pharmaceutical formulations which may be mixed with chewable or liquid veterinary formulations or food materials or liquids acceptable to the animal in question.
As used herein, the terms “pharmaceutically effective amount” or "therapeutically effective amount” mean the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, prevention or amelioration of urinary incontinence or the excessive or undesirable urge to urinate, or a decrease in the frequency of incidence of urinary incontinence. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.
The methods of this invention may be accomplished with a daily dose of the active compounds described above from U.S. Patent No. 5,384,330 of from about 0.1 mg/kg to about 10 mg/kg. Doses may be administered as a single regimen, such as only prior to bedtime or before travel, or as a continuous regimen divided by two or more doses over the course of a day. Human administration may be at dosages of from about 10 mg BID to about 1000 mg BID, preferably from about 50 mg BID to about 500 mg . BID, more preferably at a dose of from about 100 mg BID to about 300 mg BID.
The KCNQ potassium channel agonists of this invention may also be administered in the methods of this invention in combination with pharmaceutically ’ effective amounts of other medicinal agents useful for bladder control or the treatment or inhibition of urinary incontinence. For instance, the compounds may be administered ‘ 5 with desmopressin acetate, available as DDAVP® Nasal Spray and DDAVP® tablets from
Aventis Pharmaceuticals, as well as a desmopressin acetate rhinal tube from Ferring
Pharmaceuticals Inc. Other combination products include tolterodine tartrate (available as DETROL™ tablets from Pharmacia & Upjohn), oxybutinin chloride (available in the form of DITROPAN® tablets and syrup and DITROPAN XL? extended release tablets from ALZA Pharmaceuticals), propanthaline bromide (available in tablet form from
Roxane Laboratories, Inc.), hyoscyamine and hyoscyamine sulfate (available, respectively, as CYSTOPAZ® tablets and CYSTOPAZ-M® timed release capsules from
PolyMedica Pharmaceuticals (U.S.A.), Inc.), hyoscyamine hydrobromide, flavoxate HC! (available in URISPAS® 100 mg tablets from ALZA Pharmaceuticals), imipramine HCI (available in 10 mg, 25 mg and 50 mg tablets from Geneva Pharmaceuticals, Inc.), phenylpropanolamine, midodrine HCI (available in 2.5 mg and 5 mg PROAMATINE® tablets from Shire US Inc.), phenoxybenzamine HCI (available as DIBENZYLINE® capsules from WellSpring Pharmaceuticals Corporation), and prazosin HCI (available in 'MINIPRESS® capsules from Pfizer Inc.). Each of these medicaments may be administered in the pharmaceutically effective amounts and regimens known in the art, including those listed in the Physicians’ Desk Reference, 55 Edition, 2001, published by
Medical Economics Company, Inc. at Monvale, NJ 07645-1742, the relevant portions of which are incorporated herein by reference. The KCNQ channel agonists of this invention may also be used in conjunction with one or more compounds which act as vasopressin agonists including, but not limited to those described in U.S. Patent No. 6,194,407 (Fail et al.), U.S. Patent No. 6,090,803 (Failli et al.), U.S. Patent No. 6,096,736 (Ogawa et al.), and U.S. Patent No. 6,096,735 (Ogawa et al.).
Compounds as described in U.S. Patent No. 5,384,330, including retigabine, can . 30 be administered orally using conventional pharmaceutical excipients or carriers, preferably coated or contained in hard or soft gelatin capsules. Examples of oral . formulations contained in hard gelatin capsules can include those in which the active compound comprises from about 45% to 50%, by weight, of the formulation.
Microcrystalline cellulose comprises from about 43% to about 47%, povidone comprises from about 3% to about 4%, and silicon dioxide and magnesium stearate each comprise : from about 0.3% to about 0.7%, each by weight. Specific examples of capsules containing 50 mg, 100 mg and 200 mg may be formulated utilizing the following lists of , 5 components. 50 mg Retigabine Capsules ingredient Amount/Capsule
Retigabine 50.0 mg
Microcrystalline Cellulose, NF 45.5 mg
Povidone, USP 3.5 mg
Silicon Dioxide, Colloidal, anhydrous, NF 0.5mg
Magnesium Stearate, EP 0.5 mg
Theoretical Fill Weight 100.0 mg 100 mg Retigabine Capsules
Ingredient Amount/Capsule
Retigabine 100.0 mg
Microcrystalline Cellulose, NF 91.0 mg
Povidone, USP 7.0 mg
Silicon Dioxide, Colloidal, anhydrous, NF 1.0 mg
Magnesium Stearate, EP 1.0 mg
Theoretical Fill Weight 200.0 mg 200 mg Retigabine Capsules
Ingredient Amount/Capsule
Retigabine 200.0 mg
Microcrystalline Cellulose, NF 182.0 mg ) Povidone, USP 14.0 mg
Silicon Dioxide, Colloidal, anhydrous, NF 2.0 mg . Magnesium Stearate, EP 2.0mg
Theoretical Fill Weight 400.0 mg
The ingredients in the formulations above can be prepared using the following steps. . 1) Weigh separately the active ingredient (retigabine), preferably screened through an 800 micron screen, and the microcrystalline cellulose components. ] 5 2) Prepare a granulation solution by dissolving the Povidone, USP in purified water. 3) Place the ingredients from Step 1 into a suitable blender and mix thoroughly.
4) Screen the mixture from Step 3 through a 1000 um screen and place the screened mixture into the vessel of a fluidized bed granulator. 5) Heat the ingredients in the fluid bed granulator up to 27°C product temperature while mixing.
6) Add the granulation solution from Step 2 to the fluid bed. 7) Dry the granulate in the fluid bed.
8) Weigh the colloidal silicon dioxide component, preferably screened through a 1000 um screen, and the magnesium stearate component, preferably screened through a 600 um screen.
9) Add the silicon dioxide and magnesium stearate components to the fluid bed granulator's vessel containing the dried granulate from Step 7 and mix the components thoroughly.
10) Screen the mixed components from Step 9, preferably through a 800um screen.
11) Transfer the final screened components into a suitable blender and mix thoroughly.
The final component mixture from Step 11 can then be coated, encapsulated or . compressed into tablets utilizing conventional tablet excipients or carriers, as desired. It will be understood that oral dosage forms within the scope of this invention can be . 5 prepared using the components listed above in respective amounts according the dose of active ingredient in the particular formulation. For veterinary uses, the final mixture of
Step 11 can be administered neat or mixed into foods acceptable to the animal in question. Further, the mixtures can be formulated into tablets, capsules or coated products, as described above, or integrated into conventional veterinary medicaments or food products.
For intravenous administration, the compounds from U.S. Patent No. 5,384,330 described herein may be prepared and maintained in conventional lyophylized formulations and reconstituted prior to administration with an intravenously acceptable saline solution, such as a 0.9% saline solution. The pH of the intravenous formulation can be adjusted, as needed, with an intravenous and pharmaceutically acceptable acid, such as methanesulfonic acid.
KNGCQ1, 3 and 5 expression and M-current activity in rat urinary bladder
Using quantitative ntPCR, the expression of KCNQ1, KCNQ3 and KCNQ5 potassium channels was identified in the rat urinary bladder. The highest levels of expression were seen in KCNQ5 (0.2+0.1ng KCNQ5 mRNA/GAPDH mRNA). To further probe M-current activity in the bladder, retigabine (10uM, M-current agonist) was tested in isolated bladder smooth muscle cells using standard patch-clamp techniques.
Exposure to retigabine significantly increased an outward current that was insensitive to iberiotoxin and was associated with a membrane hyperpolarization of 17.8 = 3.0 mV (n=5). This hyperpolarization was reversed by the addition of linopirdine (50uM an M- current antagonist) to the tissue bath. Retigabine relaxed isolated carbachol contracted - 30 rat bladder strips with an ICs of 3.50.9 uM (n=14). This relaxation was reversed by the
M-current blockers linopirdine and XE-991.
Claims (27)
1. Use of a KCNQ potassium channel agonist in the preparation of a medicament for inducing or maintaining bladder control in a mammal.
2. Use of a KCNQ potassium channel agonist in the preparation of a medicament for treatment or prevention of urinary incontinence in a mammal
3. Use according to Claim 2 wherein the urinary incontinence is urge incontinence.
4, Use according to Claim 2 wherein the urinary incontinence is secondary to prostate hypertrophy.
5. Use according to Claim 2 wherein the urinary incontinence is mixed urge and stress incontinence.
6. Use according to any one of Claims 1 to 5 wherein the KCNQ potassium channel is a KCNQ4 potassium channel.
7. Use according to any one of Claims 1 to 5 wherein the KCNQ potassium channel is a KCNQ2/3 potassium channel.
8. Use according to any one of Claims 1 to 5 wherein the KCNQ : potassium channel is a KCNQ3/5 potassium channel.
9. Use according to any one of Claims 1 to 8 wherein the mammal is a human.
10. Use according to any one of Claims 1 to 8 wherein the mammal is feline or canine.
11. Use according to any one of Claims 1 to 10 in which the KCNQ potassium channel agonist is a compound of the formula (1): AMENDED SHEET o PCT/US01/32204
Ry Lo x ~ JON Ar—Akk—(CO ( ™ NRA, Rs 0) wherein: Rj is selected from hydrogen, C—Cg-alkyl, C,—Cg-alkanoyl or the radical Ar; R; is selected from hydrogen or C;—Cg-alkyl;
Rs is selected from C,;—Cg-alkoxy, NH, C;—Cs-alkylamino, C,—Cs- dialkylamino, amino substituted by the radical Ar, C;—Cg-alkyl, C,—Cg-alkenyl, C,—Cs-alkynyl, the radical Ar or the radical ArO-;
R4 is selected from hydrogen, C.—Cg-alkyl or the radical Ar;
Rs is selected from hydrogen or C—Cs-alkyl or the radical Ar; Alk: a straight or branched alkylene group with 1-0 carbon atoms, which can also be substituted by the radical Ar;
Ar is a phenyl radical substituted by the radicals Rg, R; and/or Rg where these radicals Rs, Ry and Rg are the same or different and represent H, C—Cs- alkyl, C;—Cr-cycloalkyl, hydroxy, C—Cs-alkoxy, C,—Cs-alkanoyloxy, halogen, hydroxy, C—Cs-halogenoalkyl, -CN, -NH,, -NH—C,—Cs-alkyl, -N(C1—Cg-alkyl),, - CO,H, -CO—C;—Cg-alkyl, -CO—0O—C;—Cs-alkyl, -COAr, -CO—OAr, -CONHj,, - CONH—C—Cg-alkyl, -CON(C—Cg-alkyl);, -CONHAr, -NH—CO—C—Cg-alkyl, - NHCO—Ar, -NHCO—C,—Cg-alkoxy, -N—H—CO—Ar, -NHCO—NH,, -NHCO—N(- Ci—Ce-alkyl);, -NHCO—NHAr, -NH—S0,—C—1—Cg-alkyl, -NH—SO,Ar, -NH— SO,-nitrophenyl, -SO—0OH, -SO,—C—Cs-alkyl, -SO,-Ar, -SO—C;—Cs-alkoxy, - SO, —OAr, -SO,—NH,, -SO,—NH—C;—Cs-alkyl, -SO,—N(C;—Cs-alkyl);, ~-SO;— NHAr, -SO,—C,—Cs-alkoxy;
nisOor1;
or a pharmaceutically acceptable salt thereof.
AMENDED SHEET
@ PCT/US01/32204
12. Use according to Claim 11 in which the compound of formula | is selected from the group of: 2-Amino-4-(4-fluorobenzylamino)-1-ethoxycarbonylaminobenzene; 2-Amino-4-(4-trifluoromethylbenzylamino)-1-ethoxycarbonylamino-benzene; 2-Amino-4-benzylamino-1-ethoxycarbonylamino-benzene; 2-Amino-4-(3,5-dichlorobenzylamino)-1-ethoxycarbonylamino benzene; 2-Amino-4-(3,5-dichlorobenzylamino)-1-propyloxycarbonylamino benzene; 2-Amino-(2-chlorobenzylamino)-1-(diethylcarbamoylamino) benzene; 2-Amino-4-(2,4-dichlorobenzylamino)-1-(dimethylcarbamoylamino) benzene; or 1,2-Diacetylamino-4-(4-fluorobenzylamino) benzene; or a pharmaceutically acceptable salt thereof.
13. Use according to Claim 11 in which the compound of formula is N-[2-amino-4-(4-fluorobenzylamino)-phenyllcarbamic acid or a pharmaceutically acceptable salt or ester form thereof.
14. Use according to Claim 13 wherein the pharmaceutically acceptable ester form is N-[2-amino-4-(4-fluorobenzylamino)-phenyllcarbamic acid ethyl ester.
15. Use according to Claim 13 or Claim 14 wherein said compound : or pharmaceutically acceptable salt or ester form thereof is effective administered in an amount from about 0.1 mg/kg to about 10 mg/kg. :
16. Use according to Claim 13 or Claim 14 wherein said compound or pharmaceutically acceptable salt or ester form thereof is effective administered in an amount from about 10 mg BID to about 1000 mg BID.
17. Use according to Claim 13 or Claim 14 wherein said compound or pharmaceutically acceptable salt or ester form thereof is effective administered in an amount from about 50 mg BID to about 500 mg BID.
18. Use according to Claim 13 or Claim 14 wherein said compound or pharmaceutically acceptable salt or ester form thereof is effective administered in an amount from about 100 mg BID to about 300 mg BID. AMENDED SHEET
@ PCT/US01/32204 —-19~ ~ 19. Use according to any one of Claims 1 to 10 in which the KCNQ potassium channel agonist is a compound of the formula (11): R' H R? N 0 3 R R rR? g OR® 6 FR 0) ) wherein: R is hydrogen, hydroxy or fluoro; R', R? R?® and R* each are independently hydrogen, C,. alkyl, halogen, trifluoromethyl, phenyl, p-methylphenyl or p-trifluoromethyiphenyl; or R' and R?, R? and R® or R® and R* are joined together to form a benzo fused ring; R%is hydrogen or C4 alkyl; and R® is chlorine or trifluoromethyi; or a nontoxic pharmaceutically acceptable salt, solvate or hydrate thereof..
20. Use according to Claim 19 in which the compound of formula ll is selected from the group of: : (1)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol- 2-one; (£)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-6-(trifluoromethyl)-2H-indol-2-one; (£)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol- 2-one; (£)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-6-(trifluoromethyl)-2H-indol-2-one; (£)-3-(5-Chloro-2-hydroxyphenyl)-4,6-dichloro-1,3-dihydro-3-hydroxy-2-H-indol-2- one; : AMENDED SHEET
@® PCT/US01/32204
(£)-3-(5-Chioro-2-hydroxyphenyt)-1,3-dihydro-3-hyd roxy-7-(trifluoromethy!)-2H-indol- 2-one; (x)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-4-trifluoromethyl)2H-indol-2- ~~ one; ()-1,3-Dihydro-3-hydroxy-3-[2-hydroxy-5-(trifluoromethyl)phenyl}-6-(trifluoromethyt)- 2H-indol-2-one; (+)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-4,6-bis(triflucromethyt)-2H- indol-2-one; (-)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol- 2-one;
: (%)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)2H-indol-
- 2-one; (-)-3-(5-Chloro-2-hydroxyphenyi)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)2H-indol-2- one;
()-3-(5-Chloro-2-methoxyphenyl)-1 ,3-dihydro-3-fluoro-6-(trifluoromethyt)2H-indol-2- one; (+)-3-(5-Chioro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-2H-benz[glindol-2one; (#)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-6-phenyl-2H-indol-2-one; (£)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-2H-benz[glindoi-2-one; (%)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-phenyl-2H-indol-2-one; (#+)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-iodo-2H-indol-2one; (£)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-6-(4-methylphenyl)-2H-indol-2-one; (+)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-7-(trifluoromethyl)-2H-indol-2- one; (%)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihyd ro-2H-benz{e]indol-2-one; (+)-3~(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-5-methyl-2H-indol-2-one; (%)-3-(5-Chloro-2-methoxyphenyl)-1 ,3-dihydro-3-fluoro-4,6-bis(trifluoromethyl)-2H- indol-2-one; : (+)-5-Bromo-3-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-2H-indol-2one; (z)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-6-[4-(trifluoromethyl)phenyl}-2H-indol- 2-one; (+)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-2H-indol-2-one; AMENDED SHEET
-& PCT/US01/32204 (£)-5-Bromo-3-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-2H-indol-2-one; (£)-3-(5-Chloro-2-hydroxyphenyl)-4,6-dichloro-1,3-dihydro-2H-indol-2-one; (£)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-6-iodo-2H-indol-2-one; (£)-3-(5-Chloro-hydroxyphenyl)-1,3-dihydro-6-iodo-2H-indol-2-one; (£)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-2H-benz[flindol-2one; (£)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-2H-benz[flindol-2one; and (£)-3~(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-2H-benz|[flindol-2-one; and the pharmaceutically acceptable salt forms thereof.
21. A substance or composition for use in a method for inducing or maintaining bladder control in a mammal, said substance or composition comprising a KCNQ potassium channel agonist, and said method comprising administering said substance or composition.
22. A substance or composition for use in a method for treatment or prevention of urinary incontinence in a mammal, said substance or composition comprising a KCNQ potassium channel agonist, and said method comprising administering said substance or composition.
23. A substance or composition for use in a method of treatment or prevention according to Claim 22 wherein the urinary incontinence is urge incontinence.
24. A substance or composition for use in a method of treatment or prevention according to Claim 22 wherein the urinary incontinence is secondary to prostate hypertrophy.
25. A substance or composition for use in a method of treatment or prevention according to Claim 22 wherein the urinary incontinence is mixed urge and stress incontinence.
26. A substance or composition for use in a method of treatment or prevention according to any one of Claims 21 to 25 wherein the KCNQ potassium channel is a KCNQ4 potassium channel.
27. A substance or composition for use in a method of treatment or prevention according to any one of Claims 21 to 25 wherein the KCNQ AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24107800P | 2000-10-17 | 2000-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200303798B true ZA200303798B (en) | 2004-08-16 |
Family
ID=34078787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200303798A ZA200303798B (en) | 2000-10-17 | 2003-05-15 | Methods for modulating bladder function. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200303798B (en) |
-
2003
- 2003-05-15 ZA ZA200303798A patent/ZA200303798B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1326597B1 (en) | Use of kcnq potassium channel agonists for the manufacture of a medicament for modulating bladder function | |
US7015242B2 (en) | Methods for treating hyperactive gastrointestinal motility | |
Boursinos et al. | Do steroids, conventional non-steroidal anti-inflammatory drugs and selective Cox-2 inhibitors adversely affect fracture healing | |
Bivalacqua et al. | Gene transfer of extracellular SOD to the penis reduces O 2−· and improves erectile function in aged rats | |
US6589986B2 (en) | Methods of treating anxiety disorders | |
US20200392092A1 (en) | Apelin receptor agonists and methods of use thereof | |
CZ2001692A3 (en) | Pharmaceutical preparation for treating a lung disease and process for preparing such pharmaceutical preparation | |
MXPA04008037A (en) | Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence. | |
RU2012110592A (en) | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | |
JP6023082B2 (en) | Compositions containing prostaglandins for treating neuropsychiatric diseases | |
ES2425482T3 (en) | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats | |
US6403640B1 (en) | Method for treating chronic prostatitis or chronic pelvic pain syndrome | |
Ozaki et al. | Monoamine oxidase inhibitors and procedures for their evaluation in vivo and in vitro | |
US9271987B2 (en) | Methods and compositions for treating Alzheimer's disease | |
ZA200303798B (en) | Methods for modulating bladder function. | |
KR102448406B1 (en) | ARA/thromboxane receptor antagonists in asthma | |
AU2007201061A1 (en) | Methods for modulating bladder function | |
EP3870180B1 (en) | Combination comprising sildenafil for use in the treatment of osteoarthritis | |
US20220347141A1 (en) | Methods of treating phosphate concentration disorders with l-baiba | |
US20240122893A1 (en) | Methods for inhibiting coronaviruses using sulforaphane | |
Quinn et al. | The action of β-adrenoceptor antagonists on rat heart mitochondrial function in vitro: a comparison of propranolol, timolol, and atenolol | |
WO2023129857A1 (en) | Methods of treating, ameliorating, and/or preventing stress-related disorder | |
ULC | Pr MYLAN-TAMSULOSIN |